
Sign up to save your podcasts
Or
In today’s episode, we are joined by Dan Mourich, the Co-Founder of Biotesserae. Dan is a trained neurologist, an immunologist who moved into the drug development sector about 18 years ago. Biotesserae focuses on developing drugs for canine cancer treatments that are simple procedures, easy to access, and financially affordable for pet owners. Tune in as we speak about what motivated Dan to start Biotesserae, how is animal drug development process different from human drug development, why is Biotesserae considered a disruptor in the space, and what lessons Dan and his team learned when looking for a partner and funding for Biotesserae.
IN THIS EPISODE:
KEY TAKEAWAYS:
LINKS MENTIONED:
Dan’s LinkedIn Profile
Dan’s company email
5
22 ratings
In today’s episode, we are joined by Dan Mourich, the Co-Founder of Biotesserae. Dan is a trained neurologist, an immunologist who moved into the drug development sector about 18 years ago. Biotesserae focuses on developing drugs for canine cancer treatments that are simple procedures, easy to access, and financially affordable for pet owners. Tune in as we speak about what motivated Dan to start Biotesserae, how is animal drug development process different from human drug development, why is Biotesserae considered a disruptor in the space, and what lessons Dan and his team learned when looking for a partner and funding for Biotesserae.
IN THIS EPISODE:
KEY TAKEAWAYS:
LINKS MENTIONED:
Dan’s LinkedIn Profile
Dan’s company email